BOEHRINGER Ingelheim Animal Health has announced that it has ceased production of the flukicide product Trodax 34 per cent w/v Solution for Injection, containing nitroxynil, for the European market.
Trodax is used to treat the mature and late-immature stages of the liver fluke Fasciola hepatica in both cattle and sheep. It is also indicated for the treatment of Haemonchus contortus infections.
Findlay MacBean, Business Head for Ruminant at Boehringer Ingelheim Animal Health, said: “Trodax is a well-regarded flukicide, and has been used successfully for many years by cattle and sheep producers. Manufacturing problems have led to Trodax being out of stock since late 2020 and it is with regret that we have to confirm that we are no longer able to manufacture the product.
“As one of the largest animal health businesses in the world we are committed to improving the lives and health of animals. We have a strong research and development focus, and a pipeline of potential products, including antiparasitics. We recognise that the discontinuation of Trodax may pose challenges for cattle and sheep producers, particularly in instances where resistance to other flukicides has been confirmed. We would advise those affected to review their fluke control plan with a vet or animal health advisor.”
Boehringer Ingelheim Animal Health’s other wormer and flukicide brands are not affected by this change. Ivomec Super Injection, which contains ivermectin and clorsulon, provides an alternative treatment option for adult liver fluke in cattle and is also effective against gastrointestinal worm species, lungworm, and key external parasites.